Zacks Investment Research lowered shares of Fibrocell Science (NASDAQ:FCSC) from a buy rating to a hold rating in a research report released on Tuesday.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Separately, HC Wainwright set a $6.00 price target on Fibrocell Science and gave the stock a buy rating in a research report on Tuesday, January 30th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $3.94.
Fibrocell Science (NASDAQ:FCSC) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.07. research analysts anticipate that Fibrocell Science will post -1.63 earnings per share for the current fiscal year.
In other Fibrocell Science news, major shareholder Randal J. Kirk purchased 2,727,273 shares of Fibrocell Science stock in a transaction dated Monday, December 11th. The shares were acquired at an average cost of $0.77 per share, with a total value of $2,100,000.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.10% of the company’s stock.
Several hedge funds have recently modified their holdings of FCSC. Third Security LLC increased its position in shares of Fibrocell Science by 49.2% during the fourth quarter. Third Security LLC now owns 8,267,413 shares of the company’s stock worth $5,292,000 after purchasing an additional 2,727,273 shares in the last quarter. Pura Vida Investments LLC acquired a new position in shares of Fibrocell Science during the third quarter worth $909,000. FNY Partners Fund LP acquired a new position in shares of Fibrocell Science during the fourth quarter worth $129,000. Finally, Parametric Portfolio Associates LLC increased its position in shares of Fibrocell Science by 264.0% during the second quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock worth $194,000 after purchasing an additional 35,000 shares in the last quarter. 32.46% of the stock is currently owned by institutional investors and hedge funds.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.